Method of solving a split-brain condition
    3.
    发明申请
    Method of solving a split-brain condition 有权
    解决分裂状况的方法

    公开(公告)号:US20050268153A1

    公开(公告)日:2005-12-01

    申请号:US11101720

    申请日:2005-04-07

    摘要: In a cluster system comprising at least two nodes connected via a communication network and having a name and a host weight assigned to it, a method is implemented comprising the steps of inspecting the communication link, determining which node has to be shut down after a failure, creating an advertisement report for the node to be shut down, sending the advertisement report to at least one node of the cluster system, calculating a delay time depending on the weight of the first node and sending the shut down command to the node for which a failure report was received. In one embodiment of the invention the advertisement reports include a master node, which allows identifying and specifying the surviving subcluster. The method will send shut down signals to those nodes of a subcluster with lower weight than the surviving subcluster. A failsafe mechanism is implemented.

    摘要翻译: 在包括通过通信网络连接并具有分配给它的名称和主机权重的至少两个节点的集群系统中,实现一种方法,包括检查通信链路的步骤,确定哪个节点必须在故障之后被关闭 创建关闭节点的广告报告,将广告报告发送给集群系统的至少一个节点,根据第一个节点的权重计算延迟时间,并向其节点发送关闭命令, 收到失败报告。 在本发明的一个实施例中,广告报告包括主节点,其允许识别和指定幸存子集群。 该方法将发送关闭信号到具有比剩余子集群更低的权重的子集群的那些节点。 实施故障安全机制。

    Complete human monoclonal IgG4lambda specific for CTLA-4 and uses thereof for detection of soluble CTLA-4 and isolation of regulatory cells
    4.
    发明申请
    Complete human monoclonal IgG4lambda specific for CTLA-4 and uses thereof for detection of soluble CTLA-4 and isolation of regulatory cells 审中-公开
    完整的针对CTLA-4的人单克隆IgG4l1及其用于检测可溶性CTLA-4和分泌调节细胞的用途

    公开(公告)号:US20120009207A1

    公开(公告)日:2012-01-12

    申请号:US13107504

    申请日:2011-05-13

    IPC分类号: A61K35/14 A61P37/06

    摘要: The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases.

    摘要翻译: 本发明提供了完全人抗体性质的CTLA-4非阻断剂,因此在人体中是非免疫原性的。 使用这种非阻断剂的免疫测定方法测量人受试者样品中的CTLA-4含量。 本发明还提供了一种分离人类调节性T细胞的新方法。 所产生的富含和消耗的细胞群可用于治疗或改善人类疾病。

    Color filter substrate and fabricating method thereof
    5.
    发明授权
    Color filter substrate and fabricating method thereof 有权
    滤色器基板及其制造方法

    公开(公告)号:US07892709B2

    公开(公告)日:2011-02-22

    申请号:US11610510

    申请日:2006-12-14

    IPC分类号: G02B5/20

    摘要: A method of fabricating a color filter substrate is provided. First, a transparent substrate having a display region, a peripheral region and a buffer region is provided. Next, a shielding pattern layer is formed in the peripheral region of the transparent substrate, and a color filter layer is formed in the display region of the transparent substrate. Further, at least one buffer pattern is formed in the buffer region.

    摘要翻译: 提供了制造滤色器基板的方法。 首先,提供具有显示区域,周边区域和缓冲区域的透明基板。 接下来,在透明基板的周边区域中形成屏蔽图案层,并且在透明基板的显示区域中形成滤色器层。 此外,在缓冲区域中形成至少一个缓冲图案。

    Method of solving a split-brain condition
    6.
    发明授权
    Method of solving a split-brain condition 有权
    解决分裂状况的方法

    公开(公告)号:US07843811B2

    公开(公告)日:2010-11-30

    申请号:US11101720

    申请日:2005-04-07

    IPC分类号: G01R31/08 G06F11/00

    摘要: In a cluster system comprising at least two nodes connected via a communication network and having a name and a host weight assigned to it, a method is implemented comprising the steps of inspecting the communication link, determining which node has to be shut down after a failure, creating an advertisement report for the node to be shut down, sending the advertisement report to at least one node of the cluster system, calculating a delay time depending on the weight of the first node and sending the shut down command to the node for which a failure report was received. In one embodiment of the invention the advertisement reports include a master node, which allows identifying and specifying the surviving subcluster. The method will send shut down signals to those nodes of a subcluster with lower weight than the surviving subcluster. A failsafe mechanism is implemented.

    摘要翻译: 在包括通过通信网络连接并具有分配给它的名称和主机权重的至少两个节点的集群系统中,实现一种方法,包括检查通信链路的步骤,确定哪个节点必须在故障之后被关闭 创建关闭节点的广告报告,将广告报告发送给集群系统的至少一个节点,根据第一个节点的权重计算延迟时间,并向其节点发送关闭命令, 收到失败报告。 在本发明的一个实施例中,广告报告包括主节点,其允许识别和指定幸存子集群。 该方法将发送关闭信号到具有比剩余子集群更低的权重的子集群的那些节点。 实施故障安全机制。

    Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes
    8.
    发明授权
    Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes 有权
    通过人淋巴细胞的定点体外免疫产生人自身抗体的方法

    公开(公告)号:US08021860B2

    公开(公告)日:2011-09-20

    申请号:US12318679

    申请日:2009-01-06

    IPC分类号: C12P21/04

    摘要: A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

    摘要翻译: 公开了一种获得给定生理受体的激动剂,拮抗剂和反向激动剂的方法。 对于该方法,使用计算机设计合成免疫原,其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152,特别是分别引发作为拮抗剂,反向激动剂和激动剂的抗体的CDR1,CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。

    Method For Producing Human Antibodies With Properties Of Agonist, Antagonist, or Inverse Agonist
    9.
    发明申请
    Method For Producing Human Antibodies With Properties Of Agonist, Antagonist, or Inverse Agonist 有权
    用激动剂,拮抗剂或反激动剂的性质产生人类抗体的方法

    公开(公告)号:US20110033895A1

    公开(公告)日:2011-02-10

    申请号:US12888713

    申请日:2010-09-23

    IPC分类号: C12P21/08

    摘要: A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

    摘要翻译: 公开了一种获得给定生理受体的激动剂,拮抗剂和反向激动剂的方法。 对于该方法,使用计算机设计合成免疫原,其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152,特别是分别引发作为拮抗剂,反向激动剂和激动剂的抗体的CDR1,CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。

    Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist
    10.
    发明申请
    Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist 有权
    用于产生具有激动剂,拮抗剂或反向激动剂的性质的人抗体的方法

    公开(公告)号:US20090286224A1

    公开(公告)日:2009-11-19

    申请号:US12318679

    申请日:2009-01-06

    摘要: A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

    摘要翻译: 公开了一种获得给定生理受体的激动剂,拮抗剂和反向激动剂的方法。 对于该方法,使用计算机设计合成免疫原,其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152,特别是分别引发作为拮抗剂,反向激动剂和激动剂的抗体的CDR1,CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。